Eric Weldy
Ophthalmology · Greensboro, NCNPI 1154854990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,187 and has fallen 50.4% since, to $589 in 2025.
Across 85 payments — averaging $41.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$567
- Apellis Pharmaceuticals, Inc.$512
- Regeneron Healthcare Solutions, Inc.$495
- Astellas Pharma US Inc$344
- Regeneron$336
- Alcon$299
- plus $1K from 8 others
Across 114 payments — averaging $37.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$4K
What the payments were for
- Food & beverage$3,52199%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 10 | $567 |
| Apellis Pharmaceuticals, Inc. | 12 | $512 |
| Regeneron Healthcare Solutions, Inc. | 12 | $495 |
| Astellas Pharma US Inc | 14 | $344 |
| Regeneron | 4 | $336 |
| Alcon | 6 | $299 |
| Alimera Sciences, Inc. | 9 | $272 |
| Eyepoint US, Inc. | 3 | $214 |
| Notal Vision, Inc. | 7 | $173 |
| Harrow Eye, LLC | 3 | $142 |
| Genentech, Inc. | 1 | $107 |
| Bausch & Lomb Americas Inc. | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Coherus Oncology, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,562 in reported general payments places this provider in the 75th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 223 | $7,975 |
| Ofloxacin | 160 | $1,850 |
| MoxifloxacinMoxifloxacin Hcl | 32 | $893 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $220 |
| ErythromycinErythromycin Base | 20 | $217 |
| Brimonidine Tartrate | 28 | $132 |
| Latanoprost | 12 | $86 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Greensboro
- Karl StonecipherGreensboro$653K
- Derek DelmonteGreensboro$27K
- Paula PecenGreensboro$9K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Keith WalterWinston Salem$397K
- Leon HerndonDurham$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.